Clinical Trials Browser

Interventional × Carcinoma, Hepatocellular × Axitinib × Clear all

NCT04458259 2025-08-28

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1 Terminated

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT05249569 2023-05-03

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

Phase 2 Terminated

1 enrolled 4 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01334112 2019-12-12

AXITINIB

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01210495 2019-01-09

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Phase 2 Completed

224 enrolled 35 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01352728 2018-06-20

Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT01273662 2017-02-09

Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Phase 1 Withdrawn

CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular